|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thyroglobulin and Pax-8 were useful for distinguishing between metastatic carcinomas; however, Pax-8 may be a superior marker due to its higher sensitivity.
|
31788765 |
2020 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To improve our understanding of the role of EMT in these tumors, we studied a series of 89 carcinomas including 14 undifferentiated/dedifferentiated endometrial carcinomas (UECs/DECs), 49 CSs (21 endometrial, 29 tubo-ovarian and peritoneal), 17 endometrioid carcinomas (grade 1-3), and 9 high-grade serous carcinomas of the uterus, using a panel of antibodies targeting known epithelial markers (Pan-Keratin AE1/AE3 and E-cadherin), mesenchymal markers (N-cadherin), EMT transcription factors (TFs) (ZEB1, ZEB2, TWIST1), PAX8, estrogen receptors (ER), progesterone receptors (PR), and the p53 protein.
|
30739164 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p < 0.0001), PAX8 (p = 0.038; more in adenosquamous carcinoma), p40 (p < 0.0001; more in adenosquamous carcinoma), p63 (p = 0.0018; more in adenosquamous carcinoma) and MUC6 (p < 0.0001; less in adenosquamous carcinoma), HNF-1beta (p = 0.0023), vimentin (p = 0.0003), p53 (p = 0.0004), and CK7 (p = 0.0002) expression.
|
30258209 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All other primary lung carcinomas (413/418) were negative for PAX-8.
|
28777151 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Few mucinous carcinomas (n = 1) and clear cell carcinomas (n = 2) expressed PAX8, and none expressed WT1.
|
28367736 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Paired box 8 (PAX8) is a crucial nephric-lineage transcription factor, and its aberrant expression has been detected in various types of cancer including Müllerian carcinomas.
|
27225188 |
2016 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A chromosomal translocation that results in production of a PAX8-PPARG fusion protein is found in follicular carcinomas.
|
23933154 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations were consistent with those obtained with immunohistochemical analyses employing markers to differentiate between carcinomas of the breast and ovary, including WT1 and PAX8.
|
24220311 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, IHC labeling for PAX8, Cam5.2, CD10, and RCC marker antigen supports classification of the t(6;11) RCC as carcinomas despite frequent negativity for broad-spectrum cytokeratins and EMA.
|
24618616 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Later, a fusion of the genes PAX8 and PPARG resulting from this translocation was frequently observed in follicular carcinomas and considered as a marker of follicular thyroid cancer.
|
21763631 |
2011 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
|
16609007 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that the close surrounding of PPAR(gamma) is a breakpoint hot spot region, leading to recurrent alterations of this gene in thyroid tumors of follicular origin including carcinomas as well as adenomas with or without involvement of PAX8.
|
17123335 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Taken together, our findings further support that follicular carcinomas with a PAX8-PPAR(gamma) rearrangement constitute a distinct biological entity.
|
15608688 |
2005 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemistry showed that nuclear PPARgamma staining was weak in normal tissues, adenomas, papillary carcinomas and in some follicular carcinomas, and strong in the follicular carcinomas positive for the PAX8-PPARgamma1 translocation, but also in some follicular tumors in which no translocation could be evidenced.
|
15362967 |
2004 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PPAR gamma gene mutations have been found in 4 of 55 sporadic colon cancers, and a chimeric PAX8-PPAR gamma 1 gene frequently generates a chromosomal translocation in thyroid follicular carcinomas, implicating PPAR gamma in tumor suppression.
|
12364466 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings that PAX8-PPAR gamma 1 rearrangements are present in both follicular carcinomas and adenomas suggest that this oncogene is not a reliable marker to differentiate between FTC and FTA in fine-needle aspiration biopsies of follicular neoplasms of the thyroid.
|
12161538 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Most sporadic follicular carcinomas positive for PAX8-PPARgamma were overtly invasive, whereas tumors lacking the rearrangement were predominantly minimally invasive.
|
12170088 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAX8-PPARgamma1 mRNA and protein were detected in 5 of 8 thyroid follicular carcinomas but not in 20 follicular adenomas, 10 papillary carcinomas, or 10 multinodular hyperplasias.
|
10958784 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results show that TTF-1 and Pax-8 are expressed in well differentiated adenomas and that their expression decreases in less differentiated papillary and follicular carcinomas and is lost in undifferentiated anaplastic carcinomas.
|
10401674 |
1999 |